AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
Georgia’s busiest sea gateway has reached its capacity limit, adding urgency to plans for a major expansion of Poti port as the country seeks...
Overnight Iranian strikes on an air base in Jordan damaged multiple U.S. aircraft and left one without a wing, American media reported. Meanwhile, ...
Ukrainian forces struck a Russian oil refinery in Siberia and a seaport in Dagestan in the past 24 hours, President Volodymyr Zelenskyy s...
Four people were killed, including a child, in Ukrainian strikes on the Russian port city of Novorossiysk overnight, according to the governor of the Krasnodar region. Ukraine's drone forces commander, Robert Brovdi, said Russian military ships were destroyed in the attacks.
Wildfires have broken out in Türkiye’s Antalya province, forcing hundreds of people to evacuate as strong winds fuelled the flames.
A TV channel was struck during a live broadcast on Tuesday, Ukrainian President Volodymyr Zelenskyy said, as Russian strikes on Kyiv killed at least three people, the city's Mayor Vitali Klitschko said. Meanwhile, drones hit civilian infrastructure in Russia's southwestern Saratov region.
U.S. Central Command (CENTCOM) said its forces destroyed five Iranian crude oil carriers after the Islamic Revolutionary Guard Corps (IRGC) allegedly launched two ballistic missile attacks against a U.S. Navy warship over the past two days.
Overnight Iranian strikes on an air base in Jordan damaged multiple U.S. aircraft and left one without a wing, American media reported. Meanwhile, explosions were heard across parts of southern Iran according to local media reports.
Authorities in Nigeria's Ondo State have launched an investigation after 24 people died and several others were hospitalised following the consumption of a locally produced herbal drink in communities in the country's southwest.
A new study has found that baby girls exposed to paracetamol during pregnancy had, on average, smaller ovaries and uteruses and fewer ovarian follicles than those whose mothers did not take the painkiller.
The World Health Organisation (WHO) has warned that efforts to contain the Ebola outbreak in the Democratic Republic of Congo (DRC) are facing growing pressure as the virus spreads to new areas faster than treatment capacity can be expanded.
Bangladesh’s dengue outbreak is accelerating, with 42,590 people hospitalised and 117 deaths recorded this year as a sharp September surge puts further pressure on hospitals.
Prescriptions for GLP-1 weight-loss medicines among U.S. children aged eight to 11 have increased more than 300-fold since 2019, highlighting both the growing burden of childhood obesity and the debate over how early these drugs should be used.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment